eQcell Inc. Canada’s premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally, announces the appointment to its Advisory Board of Dr. Laurie R. Goodrich
Guelph, ON, Canada May 17, 2021 – eQcell Inc. Canada’s premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally, announces the appointment to its Advisory Board of Dr. Laurie R. Goodrich.
“We are delighted that Dr. Goodrich has joined our Advisory Board” said Dr. Thomas Koch, Founder and CEO of eQcell.” She is a translational scientist recognized for her research in equine orthopedic regenerative medicine to improve the life of horses and humans alike. This linkage between diseases in our companion and sporting animals and humans is central to eQcell’s vision of developing novel stem cell-based products for both animals and humans.”
“I agreed to be on the Advisory Board of eQcell because the industry of regenerative therapies needs an allogeneic option for our patients based on science and conclusive data. This team is a group of conscientious scientists, clinicians and leaders in the field and therefore it was a logical choice for me to be part of such an important effort” says Dr. Goodrich.
Dr. Goodrich is Director of the Orthopaedic Research Center at Colorado State University’s C. Wayne McIlwraith Translational Medicine Institute, a Founding Fellow in Minimally Invasive Surgery at the American College of Veterinary Surgeons, Chair of American College of Veterinary Surgeons (ACVS), a member of the Board of Directors for North American Veterinary Regenerative Medicine Association (NARVMA), and was a co-founder of, and is the immediate past Chair for, the Preclinical Models Section of the Orthopedic Research Society.
Dr. Goodrich will immediately join the team advising eQcell on its clinical trials testing the company’s novel allogeneic equine cord blood stem cell product for osteoarthritis in horses. Osteoarthritis is a major health challenge for which there is currently no regenerative treatment for either horses or humans and eQcell’s product is being developed in consideration of its application to both species.
About eQcell Inc.
eQcell was founded by Dr. Thomas Koch, Associate Professor at University of Guelph, Canada, ranked fifth in the world in veterinary medicine. The company’s work in stem cells has been supported by grants and expenditures approximating $6 million over a 15-year period, and the company is considered Canada’s premier clinical-stage regenerative medicine company in addressing conditions and diseases affecting sporting and domestic animals globally for which current treatments are ineffective, not fully effective, or palliative. eQcell has developed allogeneic equine cord blood stem cells, as well as canine adipose- derived mesenchymal stromal cells, to provide novel therapeutic options
For further information:
Dr. Thomas Koch
Thomas Koch (tkoch@eqcell.com)
eQcell Inc.
University of Guelph
50 Stone Road East Guelph, Ontario N1G 2W1
Canada
